Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Feb 20;30(6):587-92.
doi: 10.1200/JCO.2010.33.5232. Epub 2011 Nov 28.

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

Eitan Amir  1 , Naomi Miller, William Geddie, Orit Freedman, Farrah Kassam, Christine Simmons, Maria Oldfield, George Dranitsaris, George Tomlinson, Andreas Laupacis, Ian F Tannock, Mark Clemons
Affiliations
Comment

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

Eitan Amir et al. J Clin Oncol. .

Erratum in

  • ERRATUM.
    [No authors listed] [No authors listed] J Clin Oncol. 2016 Apr 1;34(10):1156. doi: 10.1200/JCO.2016.67.1685. J Clin Oncol. 2016. PMID: 27009020 Free PMC article. No abstract available.

Abstract

Purpose: Decisions about treatment for women with metastatic breast cancer are usually based on the estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2) status of the primary tumor. Retrospective data suggest that discordance between primary and metastatic lesions leads to detrimental outcome. This prospective study investigated receptor status of primary tumors and metastases in the same patient and assessed the impact of discordance on patient management and survival.

Patients and methods: Biopsies of suspected metastases were analyzed for ER, PgR, and HER2. Primary tumors and metastases were analyzed using similar methodology. The treating oncologist indicated a treatment plan before and after biopsy to determine whether the result influenced management. Patients were followed up for progression or death.

Results: Of 121 women undergoing biopsy, 80% could be analyzed for receptor status. Discordance in ER, PgR, and HER2 between the primary and the metastasis was 16%, 40%, and 10%, respectively. Biopsy led to a reported change of management in 14% of women (95% CI, 8.4% to 21.5%). Fine-needle aspiration and biopsy of bone led to reduced ability to analyze receptors. After a median follow-up of 12 months, there were no trends for an association between receptor discordance and either time to treatment failure or overall survival.

Conclusion: Biopsy of metastases is technically feasible. Clinicians alter immediate management in one of seven patients on the basis of results of the biopsy, and discordance is not then associated with detrimental effects on outcome. Tissue confirmation should be considered in women with breast cancer and suspected metastatic recurrence.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Flow diagram for the study. FISH, fluorescent in situ hybridization.
Fig 2.
Fig 2.
Changes in estrogen receptor (ER), progesterone receptor (PgR), and HER2 between the original pathology report of the primary tumor and the metastasis.
Fig 3.
Fig 3.
Waterfall plot showing absolute change in hormone receptor expression. A positive score confirms increased expression of receptor from the primary to the metastasis; a negative score confirms reduced expression. (A) Estrogen receptor; (B) progesterone receptor. Blue, concordance with primary; gold, discordance with primary.
Fig 4.
Fig 4.
Survival by discordance. (A) Time to treatment failure. (B) Overall survival.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg. 1979;137:260–262. - PubMed
    1. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer. 1983;52:479–485. - PubMed
    1. Pusztai L, Viale G, Kelly CM, et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15:1164–1168. - PMC - PubMed
    1. National Comprehensive Cancer Network. Practice Guidelines in Oncology: Breast Cancer v. 1.2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
    1. Li BD, Byskosh A, Molteni A, et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol. 1994;57:71–77. - PubMed

Publication types